Stem cell hope for Parkinson's: expanded access trial offers treatment to 11 patients
NCT ID NCT06056427
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This expanded access program provides multiple intravenous infusions of a patient's own stem cells (HB-adMSCs) to up to 11 people with Parkinson's disease who were eligible for but not randomized into a related Phase 2 trial. The goal is to evaluate safety and effectiveness in controlling disease symptoms. Participants must have already passed screening for the main study.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.